Grail Stock Jumps as FDA Papers Signal Galleri Panel Path
FDA posted Galleri briefing papers with no leftover lab-test questions. Panel meets Sept. 23; approval odds remain in focus.
/ 83 items
#XY News-Driven Stocks↓
Qiagen Sale Speculation: KKR, EQT and the $50 Question
Qiagen reviews options with Goldman and Moelis.
Johnson & Johnson Weighs $20 Billion Sale of Its Orthopedics Unit to Apollo
J&J is in talks to sell DePuy Synthes, its $9.3B hip-and-knee unit, to Apollo for about $20B. A deal could close in weeks—or J&J may spin it off.
GE HealthCare Eyes Sofie Biosciences Acquisition to Expand Imaging Chemicals
GE HealthCare is considering a deal worth up to $1 billion for Sofie Biosciences, which makes radiopharmaceuticals used in cancer PET scans.
Citi Calls Olema Drop After AstraZeneca Trial Miss a Buying Opportunity
Citi calls Olema’s drop after AstraZeneca’s SERENA-4 miss excessive, keeps Buy and $59 target, and sees $20 value from later-line use.
Auvelity’s Early Alzheimer’s Agitation Launch Draws Bullish Analyst Notes
Mizuho, Needham and Guggenheim cite 32–34% script growth and robust 65+ uptake as Auvelity’s Alzheimer’s agitation launch gets off to a strong start.